Strengthening bones and muscles

Strengthening bones and muscles is a descriptive term for a therapeutic goal or a broad physiological outcome rather than a specific molecular target like a receptor or enzyme [1]. This process involves the integrated regulation of the musculoskeletal system, including the balance of bone resorption and formation by osteoclasts and osteoblasts, and the regulation of muscle fiber hypertrophy through protein synthesis pathways [2]. In pharmacological development, this outcome is pursued by targeting specific, discrete molecules such as the RANK ligand (RANKL), sclerostin (SOST), or the myostatin/activin signaling pathway [3]. Because the term describes a multi-system biological effect involving various distinct biochemical pathways and tissue types, it lacks the specificity required for a canonical drug target [4]. For biotech analysis and drug-target mapping, this entry should be replaced with specific molecular entities such as the Vitamin D receptor, parathyroid hormone receptor, or growth hormone receptor [5]. Sources: [1] NIH Osteoporosis and Related Bone Diseases National Resource Center; [2] StatPearls, 'Muscle Strength and Hypertrophy'; [3] Journal of Clinical Investigation, 'Targeting the RANKL/RANK/OPG pathway'; [4] Nature Reviews Drug Discovery, 'Targeting Myostatin for Muscle Wasting'; [5] UniProt Database entries for SOST and GDF8.

Other names

Musculoskeletal enhancementBone and muscle health maintenanceAnabolic musculoskeletal effect

The term refers to a broad physiological outcome; drugs achieving this effect act via diverse mechanisms such as inhibiting RANK ligand to reduce bone resorption, inhibiting sclerostin to promote bone formation, or modulating myostatin to increase muscle mass.